Colorectal Cancer Clinical Trials in Georgia

Showing 61-80 of 160 trials

Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)

NCT02437136

The purpose of this study is to determine the safety and tolerability of entinostat used in combination with pembrolizumab in participants with NSCLC. Additionally, the purpose of the study is to assess how effective entinostat and pembrolizumab are in combination in participants with NSCLC, Melanoma, and Mismatch-Repair Proficient CRC.

Non-Small Cell Lung CancerMelanomaMismatch Repair-Proficient Colorectal Cancer

Syndax Pharmaceuticals191 participantsStarted Aug 2015

New Haven, Connecticut, United States • Atlanta, Georgia, United States • Baltimore, Maryland, United States +8 more locations

APPROVED_FOR_MARKETING65 miles

Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer

NCT02286492

The objective of the program is to provide access to TAS-102 to patients with metastatic colorectal cancer who are refractory to or failing standard chemotherapy, are new to therapy with TAS-102 and in whom therapy with TAS-102 is clinically indicated.

Colorectal Cancer Metastatic

Taiho Oncology, Inc.

Birmingham, Alabama, United States • Scottsdale, Arizona, United States • Fresno, California, United States +30 more locations

Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)

Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer

Colorectal Cancer Trials in Other Cities

Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer

Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation

ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer

A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

Comparative Effectiveness of FITs With Colonoscopy

Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study

Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors

A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid Tumors

Other Conditions in Georgia